A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial. Gilead has the exclusive right to assume further development of the program thereafter. HB-500 ...

The current U.S. government, under the leadership of Donald Trump, has decided to freeze funding for the President’s Emergency Plan for AIDS Relief (PEPFAR), a program launched in 2003 under former ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Curing HIV will be harder than curing cancer. Apart from a few 'miracle' cases, antiretrovirals only suppress HIV, they don't kill it. But new research is promising.

Pseudoscience has recently re-emerged in the U.S. While much of it concerns vaccines, an "oldie" is again making the rounds: ...

Five years after the party took a hard pro-police stance in the wake of the Black Lives Matter movement, Vice President JD Vance believes it’s okay to support individuals who beat and kill cops, so ...

CD39-Targeted Therapies Near Key Milestones, First Approval Projected by 2029Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market ...

A unique reaction in which antibodies bind to other antibodies may help scientists at Scripps Research better understand how ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.